Arcus Biosciences Inc (RCUS) - Total Liabilities
Based on the latest financial reports, Arcus Biosciences Inc (RCUS) has total liabilities worth $473.00 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Arcus Biosciences Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Arcus Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. See Arcus Biosciences Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Arcus Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Arcus Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Elmos Semiconductor SE
F:ELG
|
Germany | €204.27 Million |
|
Metro Brands Limited
NSE:METROBRAND
|
India | Rs19.36 Billion |
|
Koninklijke Heijmans N.V.
AS:HEIJM
|
Netherlands | €1.12 Billion |
|
Go Digit General Insurance Ltd
NSE:GODIGIT
|
India | Rs202.66 Billion |
|
Old Mutual Ltd
JSE:OMU
|
South Africa | ZAC1.19 Trillion |
|
CITY DEV.LTD.ADR/1 SD-50
F:CDE0
|
Germany | €16.79 Billion |
|
Mirae Asset Life Insurance Co Ltd
KO:085620
|
Korea | ₩30.73 Trillion |
|
Huaxi Securities Co Ltd Class A
SHE:002926
|
China | CN¥87.92 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Arcus Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Arcus Biosciences Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.90 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arcus Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arcus Biosciences Inc (2016–2025)
The table below shows the annual total liabilities of Arcus Biosciences Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $508.00 Million | -23.61% |
| 2024-12-31 | $665.00 Million | +5.06% |
| 2023-12-31 | $633.00 Million | -7.99% |
| 2022-12-31 | $688.00 Million | -8.32% |
| 2021-12-31 | $750.45 Million | +177.96% |
| 2020-12-31 | $269.99 Million | +587.55% |
| 2019-12-31 | $39.27 Million | -1.79% |
| 2018-12-31 | $39.98 Million | +9.19% |
| 2017-12-31 | $36.62 Million | +257.53% |
| 2016-12-31 | $10.24 Million | -- |
About Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, a… Read more